BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu Q, Liao Q, Zhao Y. Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 2017;17:68. [PMID: 28694739 DOI: 10.1186/s12935-017-0437-3] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
Number Citing Articles
1 Jia C, Deacon GB, Zhang Y, Gao C. Platinum(IV) antitumor complexes and their nano-drug delivery. Coordination Chemistry Reviews 2021;429:213640. [DOI: 10.1016/j.ccr.2020.213640] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Mohseni G, Li J, Ariston Gabriel AN, Du L, Wang YS, Wang C. The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer. Front Immunol 2021;12:781032. [PMID: 34858438 DOI: 10.3389/fimmu.2021.781032] [Reference Citation Analysis]
3 Wu N, Xu XF, Xin JQ, Fan JW, Wei YY, Peng QX, Duan LF, Wang W, Zhang H. The effects of nuclear factor-kappa B in pancreatic stellate cells on inflammation and fibrosis of chronic pancreatitis. J Cell Mol Med 2021;25:2213-27. [PMID: 33377616 DOI: 10.1111/jcmm.16213] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Yang J, Li Y, Sun Z, Zhan H. Macrophages in pancreatic cancer: An immunometabolic perspective. Cancer Lett 2021;498:188-200. [PMID: 33122097 DOI: 10.1016/j.canlet.2020.10.029] [Reference Citation Analysis]
5 Gitto SB, Beardsley JM, Nakkina SP, Oyer JL, Cline KA, Litherland SA, Copik AJ, Khaled AS, Fanaian N, Arnoletti JP, Altomare DA. Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells. Cell Commun Signal 2020;18:95. [PMID: 32552827 DOI: 10.1186/s12964-020-00594-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Du W, Phinney NZ, Huang H, Wang Z, Westcott J, Toombs JE, Zhang Y, Beg MS, Wilkie TM, Lorens JB, Brekken RA. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. Mol Cancer Res 2021;19:1412-21. [PMID: 33811159 DOI: 10.1158/1541-7786.MCR-20-0860] [Reference Citation Analysis]
7 Wu W, Liu Q, Zhang J, Zhao Y. Survey on the current status of the diagnosis and treatment of pancreatic cancer in public tertiary hospitals in China: a cross-sectional questionnaire-based, observational study. Journal of Pancreatology 2021;4:164-9. [DOI: 10.1097/jp9.0000000000000079] [Reference Citation Analysis]
8 Cong L, Liu Q, Zhang R, Cui M, Zhang X, Gao X, Guo J, Dai M, Zhang T, Liao Q, Zhao Y. Tumor size classification of the 8th edition of TNM staging system is superior to that of the 7th edition in predicting the survival outcome of pancreatic cancer patients after radical resection and adjuvant chemotherapy. Sci Rep 2018;8:10383. [PMID: 29991730 DOI: 10.1038/s41598-018-28193-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
9 Jana A, Nookaew I, Singh J, Behkam B, Franco AT, Nain AS. Crosshatch nanofiber networks of tunable interfiber spacing induce plasticity in cell migration and cytoskeletal response. FASEB J 2019;33:10618-32. [PMID: 31225977 DOI: 10.1096/fj.201900131R] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
10 Zhao Y, Sun H, Zheng J, Shao C. Analysis of RNA m6A methylation regulators and tumour immune cell infiltration characterization in prostate cancer. Artif Cells Nanomed Biotechnol 2021;49:407-35. [PMID: 33905280 DOI: 10.1080/21691401.2021.1912759] [Reference Citation Analysis]
11 Ma Z, Zhou Z, Zhuang H, Li Z, Ma Z, Huang B, Liu C, Gong Y, Zou Y, Zheng Z, Huang S, Zhang C, Hou B. Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma. Dis Markers 2021;2021:6682697. [PMID: 33747255 DOI: 10.1155/2021/6682697] [Reference Citation Analysis]
12 Lee N, Nikfarjam M, He H. Functions of the CXC ligand family in the pancreatic tumor microenvironment. Pancreatology 2018;18:705-16. [DOI: 10.1016/j.pan.2018.07.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
13 Javadrashid D, Baghbanzadeh A, Derakhshani A, Leone P, Silvestris N, Racanelli V, Solimando AG, Baradaran B. Pancreatic Cancer Signaling Pathways, Genetic Alterations, and Tumor Microenvironment: The Barriers Affecting the Method of Treatment. Biomedicines 2021;9:373. [PMID: 33918146 DOI: 10.3390/biomedicines9040373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Das S, Berlin J, Cardin D. Harnessing the Immune System in Pancreatic Cancer. Curr Treat Options Oncol 2018;19:48. [PMID: 30128712 DOI: 10.1007/s11864-018-0566-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
15 Chopra N, Choudhury S, Bhargava S, Wajid S, Ganguly NK. Potentials of "stem cell-therapy" in pancreatic cancer: An update. Pancreatology. 2019;19:1034-1042. [PMID: 31668563 DOI: 10.1016/j.pan.2019.09.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
16 Law HC, Lagundžin D, Clement EJ, Qiao F, Wagner ZS, Krieger KL, Costanzo-Garvey D, Caffrey TC, Grem JL, DiMaio DJ, Grandgenett PM, Cook LM, Fisher KW, Yu F, Hollingsworth MA, Woods NT. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response. Clin Cancer Res 2020;26:1065-76. [PMID: 31848187 DOI: 10.1158/1078-0432.CCR-19-1496] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
17 Cai J, Lu W, Du S, Guo Z, Wang H, Wei W, Shen X. Tenascin-C Modulates Cell Cycle Progression to Enhance Tumour Cell Proliferation through AKT/FOXO1 Signalling in Pancreatic Cancer.J Cancer. 2018;9:4449-4462. [PMID: 30519351 DOI: 10.7150/jca.25926] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Hernandez-Unzueta I, Benedicto A, Romayor I, Herrero A, Sanz E, Arteta B, Olaso E, Márquez J. Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance. Pancreas 2019;48:555-67. [PMID: 30946238 DOI: 10.1097/MPA.0000000000001277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Zhang R, Liu Q, Peng J, Wang M, Li T, Liu J, Cui M, Zhang X, Gao X, Liao Q, Zhao Y. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. J Cancer 2020;11:2371-81. [PMID: 32201508 DOI: 10.7150/jca.40517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
20 Fu Y, Liu S, Zeng S, Shen H. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma. Mol Cancer 2018;17:62. [PMID: 29458370 DOI: 10.1186/s12943-018-0815-z] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 10.8] [Reference Citation Analysis]
21 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Shen M, Kang Y. Complex interplay between tumor microenvironment and cancer therapy. Front Med 2018;12:426-39. [PMID: 30097962 DOI: 10.1007/s11684-018-0663-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
23 Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X, Shukla HD, Vujaskovic Z. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers (Basel) 2020;12:E1015. [PMID: 32326142 DOI: 10.3390/cancers12041015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 Gardi N, Ketkar M, McKinnon RA, Pandol SJ, Dutt S, Barreto SG. Down-regulation of metabolic pathways could offset the poor prognosis conferred by co-existent diabetes mellitus in pancreatic (head) adenocarcinoma. ANZ J Surg 2021. [PMID: 34514690 DOI: 10.1111/ans.17194] [Reference Citation Analysis]
25 Porcelli L, Iacobazzi RM, Di Fonte R, Serratì S, Intini A, Solimando AG, Brunetti O, Calabrese A, Leonetti F, Azzariti A, Silvestris N. CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. Cancers (Basel) 2019;11:E330. [PMID: 30866547 DOI: 10.3390/cancers11030330] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 15.7] [Reference Citation Analysis]
26 Liu Q, Wu H, Li Y, Zhang R, Kleeff J, Zhang X, Cui M, Liu J, Li T, Gao J, Pan B, Wu W, Wang W, Zhou L, Guo J, Dai M, Zhang T, Liao Q, Lu Z, Zhao Y. Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment. Cancer Immunol Immunother 2020;69:1477-92. [PMID: 32285172 DOI: 10.1007/s00262-020-02542-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
27 Murthy D, Attri KS, Singh PK. Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. Front Physiol 2018;9:335. [PMID: 29670543 DOI: 10.3389/fphys.2018.00335] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
28 Kamatham S, Shahjehan F, Kasi PM. Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer. Front Pharmacol 2020;11:23. [PMID: 32116700 DOI: 10.3389/fphar.2020.00023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Wu J, Cai J. Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. Dig Dis Sci 2021;66:359-68. [PMID: 32140943 DOI: 10.1007/s10620-020-06183-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
30 Gao M, Chen Y, Wu C. Size-dependent chemosensitization of doxorubicin-loaded polymeric nanoparticles for malignant glioma chemotherapy. Bioengineered 2021. [PMID: 34783631 DOI: 10.1080/21655979.2021.2006568] [Reference Citation Analysis]
31 Du W, Pasca di Magliano M, Zhang Y. Therapeutic Potential of Targeting Stromal Crosstalk-Mediated Immune Suppression in Pancreatic Cancer. Front Oncol 2021;11:682217. [PMID: 34290984 DOI: 10.3389/fonc.2021.682217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Zhang R, Liu Q, Li T, Liao Q, Zhao Y. Role of the complement system in the tumor microenvironment. Cancer Cell Int 2019;19:300. [PMID: 31787848 DOI: 10.1186/s12935-019-1027-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
33 Wang Y, Jhang DF, Tsai CH, Chiang NJ, Tsao CH, Chuang CC, Chen LT, Chang WW, Liao LD. In Vivo Assessment of Hypoxia Levels in Pancreatic Tumors Using a Dual-Modality Ultrasound/Photoacoustic Imaging System. Micromachines (Basel) 2021;12:668. [PMID: 34200388 DOI: 10.3390/mi12060668] [Reference Citation Analysis]
34 Vietsch EE, Peran I, Suker M, van den Bosch TPP, van der Sijde F, Kros JM, van Eijck CHJ, Wellstein A. Immune-Related Circulating miR-125b-5p and miR-99a-5p Reveal a High Recurrence Risk Group of Pancreatic Cancer Patients after Tumor Resection. Appl Sci (Basel) 2019;9:4784. [PMID: 34484811 DOI: 10.3390/app9224784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Zhang X, Liu Q, Liao Q, Zhao Y. Pancreatic Cancer, Gut Microbiota, and Therapeutic Efficacy. J Cancer. 2020;11:2749-2758. [PMID: 32226493 DOI: 10.7150/jca.37445] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
36 Du W, Brekken RA. Does Axl have potential as a therapeutic target in pancreatic cancer? Expert Opin Ther Targets. 2018;22:955-966. [PMID: 30244621 DOI: 10.1080/14728222.2018.1527315] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
37 Macherla S, Laks S, Naqash AR, Bulumulle A, Zervos E, Muzaffar M. Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer. Int J Mol Sci 2018;19:E3505. [PMID: 30405053 DOI: 10.3390/ijms19113505] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
38 Jiang PC, Bao TY, Zhi JM, Bu SR. Prognostic value and immunological characteristics of a novel autophagy-related signature in pancreatic cancer. J Biosci 2021;46. [DOI: 10.1007/s12038-021-00189-9] [Reference Citation Analysis]
39 Thakur N, Paik KY, Hwang G, Chong Y. High Expression of PD-L1 Is Associated with Better Survival in Pancreatic/Periampullary Cancers and Correlates with Epithelial to Mesenchymal Transition. Diagnostics (Basel) 2021;11:597. [PMID: 33810560 DOI: 10.3390/diagnostics11040597] [Reference Citation Analysis]
40 Li C, Cui L, Yang L, Wang B, Zhuo Y, Zhang L, Wang X, Zhang Q, Zhang S. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer. Pancreas 2020;49:120-7. [DOI: 10.1097/mpa.0000000000001464] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
41 Looi CK, Chung FF, Leong CO, Wong SF, Rosli R, Mai CW. Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment. J Exp Clin Cancer Res 2019;38:162. [PMID: 30987642 DOI: 10.1186/s13046-019-1153-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 18.3] [Reference Citation Analysis]
42 Orhan A, Vogelsang RP, Andersen MB, Madsen MT, Hölmich ER, Raskov H, Gögenur I. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis. Eur J Cancer 2020;132:71-84. [PMID: 32334338 DOI: 10.1016/j.ejca.2020.03.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
43 Song H, Liu Q, Liao Q. Circular RNA and tumor microenvironment. Cancer Cell Int 2020;20:211. [PMID: 32518520 DOI: 10.1186/s12935-020-01301-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
44 Jang SD, Song J, Kim HA, Im CN, Khawar IA, Park JK, Kuh HJ. Anti-Cancer Activity Profiling of Chemotherapeutic Agents in 3D Co-Cultures of Pancreatic Tumor Spheroids with Cancer-Associated Fibroblasts and Macrophages. Cancers (Basel) 2021;13:5955. [PMID: 34885065 DOI: 10.3390/cancers13235955] [Reference Citation Analysis]
45 Merz V, Mangiameli D, Zecchetto C, Quinzii A, Pietrobono S, Messina C, Casalino S, Gaule M, Pesoni C, Vitale P, Trentin C, Frisinghelli M, Caffo O, Melisi D. Predictive Biomarkers for a Personalized Approach in Resectable Pancreatic Cancer. Front Surg 2022;9:866173. [DOI: 10.3389/fsurg.2022.866173] [Reference Citation Analysis]
46 Carrato A, Melisi D, Prager G, Westphalen CB, Ferreras A, D'Esquermes N, Taieb J, Mercadé TM. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. Future Oncol 2021;17:1843-54. [PMID: 33663227 DOI: 10.2217/fon-2020-0749] [Reference Citation Analysis]
47 Talaat IM, Elemam NM, Saber-ayad M. Complement System: An Immunotherapy Target in Colorectal Cancer. Front Immunol 2022;13:810993. [DOI: 10.3389/fimmu.2022.810993] [Reference Citation Analysis]
48 Lawal B, Tseng SH, Olugbodi JO, Iamsaard S, Ilesanmi OB, Mahmoud MH, Ahmed SH, Batiha GE, Wu ATH. Pan-Cancer Analysis of Immune Complement Signature C3/C5/C3AR1/C5AR1 in Association with Tumor Immune Evasion and Therapy Resistance. Cancers (Basel) 2021;13:4124. [PMID: 34439277 DOI: 10.3390/cancers13164124] [Reference Citation Analysis]
49 Wu W, Jin G, Wang C, Miao Y, Wang H, Lou W, Yu X, Sun B, Li H, Qin R, Wu Z, Wang W, Xu K, Wang L, Liang T, Hao C, Huang H, Li Y, Tan G, Zhao Y, Hao J, Wang Y, Peng C, Liu X, Ou J, Yuan C, Wang X, Yang Y, Cai S, Guo K, Jiang J, Yu X, Wei J, Li F, Wu X, Zhao Y. The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study. Journal of Pancreatology 2019;2:16-21. [DOI: 10.1097/jp9.0000000000000012] [Cited by in Crossref: 12] [Article Influence: 4.0] [Reference Citation Analysis]
50 Zhang Y, Xu G, Chen M, Wei Q, Zhou T, Chen Z, Shen M, Wang P. Stage IA Patients With Pancreatic Ductal Adenocarcinoma Cannot Benefit From Chemotherapy: A Propensity Score Matching Study. Front Oncol 2020;10:1018. [PMID: 32766130 DOI: 10.3389/fonc.2020.01018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Cetin B, Gumusay O. Understanding relevant immune mechanisms in gastrointestinal oncology. J Oncol Pharm Pract 2021;27:1222-34. [PMID: 33557689 DOI: 10.1177/1078155221992862] [Reference Citation Analysis]
52 Zhang Y, Liu Q, Liao Q. Long noncoding RNA: a dazzling dancer in tumor immune microenvironment. J Exp Clin Cancer Res 2020;39:231. [PMID: 33148302 DOI: 10.1186/s13046-020-01727-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
53 Su T, Yang B, Gao T, Liu T, Li J. Polymer nanoparticle-assisted chemotherapy of pancreatic cancer. Ther Adv Med Oncol 2020;12:1758835920915978. [PMID: 32426046 DOI: 10.1177/1758835920915978] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]